In-depth investigation of the immune response to COVID-19
Official title: In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2
Run by Universitaire Ziekenhuizen KU Leuven · NCT04327570 · Data updated 2026-11-12
This study looks at the immune responses of hospitalized COVID-19 patients to see what makes some people get sicker than others.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Locations | 1 site (Leuven) |
| Status | Recruiting |
| Started | March 27, 2020 |
| Main results expected | March 30, 2028 |
| Study ends | March 30, 2028 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT04327570 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who are hospitalized with confirmed SARS-CoV-2 infection.
✕Probably not a fit
Patients under 18 years old or those unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to characterize the clinical and immunological features of patients hospitalized with COVID-19 at UZ Leuven. It will collect various biological samples, including blood and respiratory secretions, from patients with confirmed SARS-CoV-2 infection to identify factors that contribute to severe disease. The study will compare characteristics between patients with severe and non-severe COVID-19, as well as between COVID-19 positive and negative controls, to enhance understanding of the immune response to the virus.
Why it matters
Potential benefit: If successful, this study could lead to targeted medical interventions for patients at high risk of severe COVID-19.
How similar studies have gone: Other studies have shown success in characterizing immune responses to COVID-19, making this approach both relevant and necessary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>/= 18 years old AND * Hospitalised with PCR-confirmed and/or CT-confirmed SARS-CoV-2 disease Exclusion Criteria: * Age \< 18 years old * No informed consent
Where it's running
-
UZ Leuven
Leuven, Belgium Recruiting
Study contacts
- Principal investigator: Joost Wauters, MD PhD — UZ Leuven
- Study coordinator: Joost Wauters, MD PhD
- Email: joost.wauters@uzleuven.com
- Phone: 003216344275
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating Baricitinib for Long COVID Symptoms
This study is testing if the medication baricitinib can help adults with Long COVID feel better physically and mentally compared to a placebo.
-
Examining the incidence of COVID-19 infections
This study is trying to see how common COVID-19 infections are and how air pollution affects people's immune responses and health during the reopening phase after lockdowns.
-
Characterizing COVID-19 patients to predict treatment outcomes
This study looks at COVID-19 patients to see if certain factors can help predict how severe their illness will be and how well they might respond to different treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.